Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development

doi:10.4254/wjh.v7.i27.2757

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8052)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

567

WORD

376

HTML

3597

Figures (1-5)

148

Tables (1-4)

130

Sum=4818

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1262

Download

1972

Sum=3234

Nov 28, 2015 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Nov 28, 2015; 7(27): 2757-2764
Published online Nov 28, 2015. doi: 10.4254/wjh.v7.i27.2757

Open in New Tab Full Size Figure Download Figure

Figure 1 A change of the alpha-fetoprotein levels after interferon-based treatment. AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 2 A change of the des-gamma-carboxy prothrombin levels after interferon-based treatment. DCP: Des-gamma-carboxy prothrombin; HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 3 Cumulative incidence of hepatocellular carcinoma according to the history of treatment for hepatocellular carcinoma. HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 4 Cumulative incidence of hepatocellular carcinoma according to alpha-fetoprotein levels. ¹The value at 24 wk after the completion of interferon-based therapy (ng/mL). AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 5 Cumulative incidence of hepatocellular carcinoma according to des- gamma-carboxy prothrombin levels at 24 wk after the completion of interferon-based therapy. ¹The value at 24 wk after the completion of interferon-based therapy (mAU/mL). DCP: Des-gamma-carboxy prothrombin; HCC: Hepatocellular carcinoma.

Citation: Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H. Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol 2015; 7(27): 2757-2764
URL: https://www.wjgnet.com/1948-5182/full/v7/i27/2757.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i27.2757